EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access · CC BY 4.0

Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen

Chloe Orkin iD, John R Koethe iD, Princy N Kumar, Peter Sklar iD, Zhi Jin Xu, Rebeca M Plank iD, Wayne Greaves, Rima Lahoulou

Open Forum Infectious Diseases · 30.10.2025 · 12 (11)

DOI: 10.1093/ofid/ofaf639 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 20.11.2025. Verfasst von Chloe Orkin und 7 weiteren Autor:innen. Beteiligte Einrichtung: SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Factors associated with weight change were examined in phase 3 studies in which adults living with HIV-1 continued or switched to doravirine-based antiretroviral regimens.

Methods

Participants were randomized to first-line therapy with doravirine or darunavir/ritonavir, each given with 2 nucleos(t)ide reverse transcriptase inhibitors (NRTIs) (DRIVE-FORWARD) and to doravirine/lamivudine/tenofovir disoproxil fumarate (TDF) or efavirenz/emtricitabine/TDF (DRIVE-AHEAD); after 96 weeks, participants continued (n = 466) or switched to (n = 423) doravirine for 96-week open-label extensions. In DRIVE-SHIFT, virologically suppressed participants on stable antiretroviral therapy were randomized to switch to doravirine/lamivudine/TDF at day 1 or week 24 through week 144 (n = 535). Generalized logistic models were used to analyze factors associated with weight loss (≥5% decrease), stable weight (<5% change), and weight gain (≥5% increase) after continuation or switch.

Results

Most participants who continued or switched to doravirine also received TDF (>74%) and had stable weight (>57%). Weight loss (odds ratio [OR], 6.14) or stable weight (OR, 2.15) was more common in participants of non-Black versus Black heritage after switching to doravirine. More participants switching from weight-suppressive non-nucleoside reverse transcriptase inhibitors versus protease inhibitors experienced weight gain versus weight loss in DRIVE-SHIFT (OR, 0.41) and weight gain versus stable weight in DRIVE-FORWARD and DRIVE-AHEAD (OR, 0.60). No significant association between weight change and prior NRTI use was observed in DRIVE-SHIFT.

Conclusions

Overall, switching to doravirine was weight neutral, although weight change may differ by demographics and weight-suppressive properties of a prior regimen. More research in historically underrepresented groups may help explain these findings. ClinicalTrials.gov NCT02275780, NCT02403674, NCT02397096.

Schlagwörter

Stichwörter der Autor:innen

HIV-1demographicsdoravirineswitchweight

Autor:innen und Institutionen

  • SHARE Collaborative, Blizard Institute, Queen Mary University of London, London, UK.
  • Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
  • Division of Infectious Diseases and Tropical Medicine, Medstar Georgetown University Hospital, Washington, DC, USA.
  • MRL Research Laboratories, Merck & Co., Inc., Rahway, New Jersey, USA.

ORCID-Profile: Chloe Orkin, John R Koethe, Peter Sklar, Rebeca M Plank

Zitieren

APA

Orkin, C., Koethe, J. R., Kumar, P. N., Sklar, P., Xu, Z. J., Plank, R. M., Greaves, W., & Lahoulou, R. (2025). Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen. Open Forum Infectious Diseases, 12(11). https://doi.org/10.1093/ofid/ofaf639

Vancouver

Orkin C, Koethe JR, Kumar PN, Sklar P, Xu ZJ, Plank RM, et al. Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen. Open Forum Infectious Diseases. 2025;12(11). doi:10.1093/ofid/ofaf639

BibTeX
@article{Orkin2025,
  author = {Orkin, Chloe and Koethe, John R and Kumar, Princy N and Sklar, Peter and Xu, Zhi Jin and Plank, Rebeca M and Greaves, Wayne and Lahoulou, Rima},
  title = {Factors Associated With Weight Change After Continuing or Switching to a Doravirine-based Regimen},
  journal = {Open Forum Infectious Diseases},
  year = {2025},
  volume = {12},
  number = {11},
  doi = {10.1093/ofid/ofaf639}
}
Kostenlos starten →